BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15899682)

  • 1. Evaluation of the Quantase neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis.
    Ball CL; Montgomery MD; Bridge PJ; Lyon ME
    Clin Chem Lab Med; 2005; 43(5):570-2. PubMed ID: 15899682
    [No Abstract]   [Full Text] [Related]  

  • 2. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
    Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
    J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
    Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
    BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening.
    Korzeniewski SJ; Young WI; Hawkins HC; Cavanagh K; Nasr SZ; Langbo C; Teneyck KR; Grosse SD; Kleyn M; Grigorescu V
    Pediatr Pulmonol; 2011 Feb; 46(2):125-30. PubMed ID: 20848586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
    Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
    Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
    Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
    Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Implementation of the neonatal cystic fibrosis screening program in Switzerland: beginning January 2011].
    Mornand A; Barben J; Hafen G
    Rev Med Suisse; 2011 Feb; 7(283):456, 458-60. PubMed ID: 21452515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for cystic fibrosis: do we need a second IRT?
    Price JF
    Arch Dis Child; 2006 Mar; 91(3):209-10. PubMed ID: 16492882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen.
    Kloosterboer M; Hoffman G; Rock M; Gershan W; Laxova A; Li Z; Farrell PM
    Pediatrics; 2009 Feb; 123(2):e338-46. PubMed ID: 19171585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study for cystic fibrosis neonatal screening: the Cuban experience.
    Castells EM; Sánchez A; Frómeta A; Mokdse Y; Ozunas N; Licourt T; Arteaga AL; Silva E; Collazo T; Rodríguez F; Martín O; Espinosa M; Del Río L; Pérez PL; Morejón G; Almira C; Núñez Z; Melchor A; González EC
    Clin Chem Lab Med; 2020 Oct; 58(11):1857-1864. PubMed ID: 32352395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
    Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
    Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
    Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
    J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
    Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
    BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.